← Back to patent-cliff list
CAS 2620-44-2
5-Nitro-2H-1,3-benzodioxole
Codes: (XXV)859946-1-c
Application context (from source-drug indications)
Biliary tract cancerTasurgratinibBile duct cancerTasurgratinibSolid tumourTasurgratinibCholangiocarcinomaTasurgratinibBreast cancerTasurgratinibHepatic function declineTasurgratinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Tasurgratinib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-Bromo-2-methoxyethane→6-(2-Methoxyethoxy)-1H-indol-5-ol→Phenyl methylcarbamate→5-[(2-Aminopyridin-4-yl)oxy]-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide→2-(4-Chlorophenoxy)acetonitrile→5-Nitro-2H-1,3-benzodioxole→(4-Bromophenyl)methanol→2-[(4-Bromobenzyl)oxy]-5-nitrophenol→1-[(4-Bromobenzyl)oxy]-2-(2-methoxyethoxy)-4-nitrobenzene→[5-[(4-Bromophenyl)methoxy]-4-(2-methoxyethoxy)-2-nitrophenyl]acetonitrile→tert-Butyl 5-hydroxy-6-(2-methoxyethoxy)-1H-indole-1-carboxylate→4-Nitropyridine 1-oxide→tert-Butyl 6-(2-methoxyethoxy)-5-[(1-oxo-1lambda5-pyridin-4-yl)oxy]-1H-indole-1-carboxylate→1,1,3,3-Tetramethylbutylamine→tert-Butyl 6-(2-methoxyethoxy)-5-([2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl]oxy)-1H-indole-1-carboxylate→4-[[6-(2-Methoxyethoxy)-1H-indol-5-yl]oxy]-N-(2,4,4-trimethylpentan-2-yl)pyridin-2-amine→6-(2-Methoxyethoxy)-N-methyl-5-([2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl]oxy)-1H-indole-1-carboxamide
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.